76650-08-3

Basic information

• Product Name: 2-BROMO-1-(3-BROMOPHENYL)-1-PROPANONE
• Synonyms: 2-BROMO-1-(3-BROMOPHENYL)-1-PROPANONE;2-BROMO-1-(3-BROMOPHENYL)-PROPAN-1-ONE;Bupropion Impurity 16
• CAS NO: 76650-08-3
• Molecular Formula: C₉H₈Br₂O
• Molecular Weight: 291.97
• Product Categories: Aromatic Ketones (substituted)
• Mol File: 76650-08-3.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-BROMO-1-(3-BROMOPHENYL)-1-PROPANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-1-(3-BROMOPHENYL)-1-PROPANONE(76650-08-3)
• EPA Substance Registry System: 2-BROMO-1-(3-BROMOPHENYL)-1-PROPANONE(76650-08-3)

Safety Data

• Hazardous Substances Data: 76650-08-3(Hazardous Substances Data)

Usage

General Description

2-Bromo-1-(3-bromophenyl)-1-propanone is a chemical compound with the molecular formula C9H8Br2O. It is a pale yellow solid with a molecular weight of 260.97 g/mol. 2-BROMO-1-(3-BROMOPHENYL)-1-PROPANONE is commonly used as an intermediate in the synthesis of pharmaceuticals and organic compounds. Its primary applications include its use as a building block in the production of various organic molecules and as a reagent in chemical reactions. 2-Bromo-1-(3-bromophenyl)-1-propanone is also used in the research and development of new drugs and chemicals due to its versatile properties and reactivity. Additionally, it is important to handle this compound with care, as it is considered to be a hazardous material and should be used in a controlled laboratory setting.

Upstream product

• 6952-59-6 3-cyanobromobenzene 
• 19829-31-3 1-(3-bromophenyl)-1-propanone 

Downstream Products

• 76650-09-4 1-(3-Bromo-phenyl)-2-fluoro-propan-1-one 
• 454464-60-9 5-(3-bromo-phenyl)-1-(3-chloro-phenylamino)-4-methyl-1H-imidazole-2-thiol 
• 76650-10-7 2-Bromo-1-(3-bromo-phenyl)-2-fluoro-propan-1-one 
• 842155-44-6 acetic acid 2-(3-bromo-phenyl)-1-methyl-2-oxo-ethyl ester 
• 1049974-35-7 2-(N-tert-butylamino)-3'-bromopropiophenone 
• 1321959-93-6 4-(3-bromophenyl)-5-methyl-N-(4-methylpyridin-2-yl)thiazol-2-amine 
• 19829-31-3 1-(3-bromophenyl)-1-propanone 

Relevant articles and documents

α-PPP and its derivatives are selective partial releasers at the human norepinephrine transporter: A pharmacological characterization of interactions between pyrrolidinopropiophenones and uptake1 and uptake2 monoamine transporters

While classical cathinones, such as methcathinone, have been shown to be monoamine releasing agents at human monoamine transporters, the subgroup of α-pyrrolidinophenones has thus far solely been characterized as monoamine transporter reuptake inhibitors. Herein, we report data from previously undescribed α-pyrrolidinopropiophenone (α-PPP) derivatives and compare them with the pharmacologically well-researched α-PVP (α-pyrrolidinovalerophenone). Radiotracer-based in vitro uptake inhibition assays in HEK293 cells show that the investigated α-PPP derivatives inhibit the human high-affinity transporters of dopamine (hDAT) and norepinephrine (hNET) in the low micromolar range, with α-PVP being ten times more potent. Similar to α-PVP, no relevant pharmacological activity was found at the human serotonin transporter (hSERT). Unexpectedly, radiotracer-based in vitro release assays reveal α-PPP, MDPPP and 3Br-PPP, but not α-PVP, to be partial releasing agents at hNET (EC50 values in the low micromolar range). Furthermore, uptake inhibition assays at low-affinity monoamine transporters, i.e., the human organic cation transporters (hOCT) 1–3 and human plasma membrane monoamine transporter (hPMAT), bring to light that all compounds inhibit hOCT1 and 2 (IC50 values in the low micromolar range) while less potently interacting with hPMAT and hOCT3. In conclusion, this study describes (i) three new hybrid compounds that efficaciously block hDAT while being partial releasers at hNET, and (ii) highlights the interactions of α-PPP-derivatives with low-affinity monoamine transporters, giving impetus to further studies investigating the interaction of drugs of abuse with OCT1-3 and PMAT.

Synthesis of α,β-dibromo ketones by photolysis of α-bromo ketones with N-bromosuccinimide: Photoinduced β-bromination of α-bromo ketones

Irradiation of α-bromopropiophenones in the presence of NBS results in the formation of α,β-dibromopropiophenones, which can be viewed as β-bromination of α-bromopropiophenones. The reaction is believed to go through a series of reactions; photoinduced C–Br bond cleavage, elimination of HBr to give α,β-unsaturated ketone intermediates, and addition of Br2, which are formed by the reaction between HBr and NBS. From mechanistic studies of the reaction, we have also found a very convenient method for α-debromination of the α,β-dibromopropiophenones which is by simple irradiation of the dibromo ketones in acetone or 2-propanol without the use of any additives. Our results demonstrate that bromine can be added into or eliminated from the alpha, beta, or both positions to the carbonyl group by photochemical methods, which make synthetic options of bromine containing carbonyl compounds versatile.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.